Wisconsin is currently home to 1262 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
InfasurfAero™ Versus Sham Treatment in Preterm Newborns with RDS
NCT05960929
Recruiting
The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.
Gender:
ALL
Ages:
Between 29 weeks and 36 weeks
Trial Updated:
03/25/2025
Locations: Unity Point Meriter, Madison, Wisconsin
Conditions: Respiratory Distress Syndrome (Neonatal), Intubation Complication, Death; Neonatal
Register for Updates
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
NCT05547165
Recruiting
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment. There are two ways... Read More
Gender:
ALL
Ages:
Between 7 days and 32 days
Trial Updated:
03/25/2025
Locations: Children's Wisconsin, Milwaukee, Wisconsin
Conditions: Ductus Arteriosus, Patent
Register for Updates
Tracking Results of Ablations to Combat AF Registry Generation 2
NCT05111015
Recruiting
The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct concomitant open heart and/or hybrid ablation, and management of the Left Atrial Appendage concomitant to a cardiac ablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Atrial Fibrillation
Register for Updates
American Lung Association (ALA) Lung Health Cohort
NCT04543461
Recruiting
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Gender:
ALL
Ages:
Between 25 years and 35 years
Trial Updated:
03/25/2025
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Lung Diseases
Register for Updates
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589
Recruiting
The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to inform CF research, help design CF clinical trials and support the development of new treatments for people with CF who do not take CFTR modulators. Another goal of this study is to learn about research... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/24/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Cystic Fibrosis
Register for Updates
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients with Medical Xerostomia
NCT06392711
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells (MSCs) into salivary glands. The main question it aims to answer is whether injection of MSCs into salivary glands results in any improvement in dry mouth. Participants will: * have bone marrow collected using a needle * undergo a salivary gland ultrasound * complete questionnaires * receive an injection of the bone marrow cells into a s... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/24/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Xerostomia, Graft-versus-host-disease, Sjogren's Disease
Register for Updates
Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors
NCT06128551
Recruiting
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.
Gender:
ALL
Ages:
Between 18 years and 125 years
Trial Updated:
03/24/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
Study of VGA039 in Healthy Volunteers and Patients with Von Willebrand Disease (VIVID)
NCT05776069
Recruiting
The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
03/24/2025
Locations: Versiti Comprehensive Center for Bleeding Disorders, Milwaukee, Wisconsin
Conditions: Von Willebrand Diseases
Register for Updates
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
NCT05440708
Recruiting
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Hepatocellular Carcinoma
Register for Updates
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT05238922
Recruiting
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of intere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Solid Tumors
Register for Updates
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT04587128
Recruiting
The study will use previously established doses of panitumumab or cetuximab in the metastatic setting for the treatment of unresectable colorectal cancer (CRC). It is designed to investigate an alternative treatment strategy to maximize the benefit to inhibition of epidermal growth factor receptor (EGFR) for a highly selected patient population. It will enroll 71 participants with left-sided, unresectable metastatic CRC. Participants will be on study up to 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Metastatic Colorectal Cancer
Register for Updates
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
NCT03821129
Recruiting
This study will assess the safety and effectiveness of GORE® CARDIOFORM Septal Occluder in a post approval setting and evaluate the quality of operator education and training and transferability of trial experience to a post-market setting.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/24/2025
Locations: Aurora Health Care, Metro Inc., Milwaukee, Wisconsin
Conditions: Stroke, PFO - Patent Foramen Ovale
Register for Updates